Cell Cure to get equity purchase of $7.1 million to develop stem cell-based therapies BioTime, Inc her . , Cell Get rid of Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure will receive an equity expenditure of $7.1 million from BioTime, Teva Pharmaceutical Sectors Ltd., and Hadasit Bio-Holdings . This financial round extends previous investments by HBL and Teva in Cell Cure. BioTime already held a significant interest in Cell Cure which it acquired through its acquisition of Sera Cell International Pte. Ltd. in-may of 2010. Following BioTime’s acquisition of ESI and its own additional purchase in Cell Cure, Cell Cure is just about the neurological arm of BioTime’s plan for the advancement of human embryonic stem cell based therapies.
Cedillo vs. Health insurance and Human Services case highlights failure of Vaccine Injury Settlement Program The Elizabeth Birt Center for Autism Law and Advocacy is deeply disappointed in the Court of Appeals for the Government Circuit’s decision to affirm Cedillo v. Secretary of Human and Health Solutions.’ Michelle Cedillo, a 15-year-old woman, developed autism and many other severe medical complications in the instant aftermath of her measles-mumps-rubella vaccine and additional mercury-containing vaccines.’ While the Court of Appeals criticized a few of the Division of Justice’s conduct as ‘troubling,’ it didn’t find that the government’s carry out merited reversal.